Regeneron beats forecasts as Eylea sales rocket

4 November 2015

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) today posted third-quarter 2015 financials, showing that revenue came in at $1.14 billion in the period, a rise of 57%, exceeding seven analysts surveyed by Zacks Investment Research expectations of $1.06 billion.

Third-quarter profit of $210.4 million, or $1.82 per share, more than doubled. Earnings, adjusted for stock option expense and pretax expenses, came to $3.47 per share. The average estimate of 11 analysts surveyed by Zacks was for earnings of $3.11 per share. Notwithstanding the better-than-expected results Regeneron’s shares were down 3.75% at $556.33 by mid-morning New York trading.

Eylea performance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK